Head to Head Analysis: DS Healthcare Group (DSKX) vs. The Competition
DS Healthcare Group (OTCMKTS: DSKX) is one of 32 publicly-traded companies in the “Personal Products” industry, but how does it contrast to its rivals? We will compare DS Healthcare Group to similar companies based on the strength of its risk, institutional ownership, analyst recommendations, profitability, earnings, dividends and valuation.
Insider & Institutional Ownership
0.0% of DS Healthcare Group shares are owned by institutional investors. Comparatively, 56.6% of shares of all “Personal Products” companies are owned by institutional investors. 19.4% of DS Healthcare Group shares are owned by company insiders. Comparatively, 15.4% of shares of all “Personal Products” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares DS Healthcare Group and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|DS Healthcare Group||-62.31%||-1,304.25%||-117.85%|
|DS Healthcare Group Competitors||-23.34%||73.78%||1.23%|
This is a breakdown of recent ratings and recommmendations for DS Healthcare Group and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|DS Healthcare Group||0||0||0||0||N/A|
|DS Healthcare Group Competitors||362||1263||1529||24||2.38|
As a group, “Personal Products” companies have a potential upside of 15.01%. Given DS Healthcare Group’s rivals higher probable upside, analysts plainly believe DS Healthcare Group has less favorable growth aspects than its rivals.
Risk & Volatility
DS Healthcare Group has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500. Comparatively, DS Healthcare Group’s rivals have a beta of 1.25, suggesting that their average stock price is 25% more volatile than the S&P 500.
Valuation & Earnings
This table compares DS Healthcare Group and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|DS Healthcare Group||$12.95 million||-$6.93 million||-0.04|
|DS Healthcare Group Competitors||$16.34 billion||$2.21 billion||412.82|
DS Healthcare Group’s rivals have higher revenue and earnings than DS Healthcare Group. DS Healthcare Group is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
DS Healthcare Group rivals beat DS Healthcare Group on 7 of the 9 factors compared.
About DS Healthcare Group
DS Healthcare Group, Inc., doing business as DS Laboratories, is a personal care, product development and marketing company. The Company develops and markets branded personal care products that address thinning hair conditions, skin care and other personal care needs. It develops technologies and products for hair care and personal care needs. Its technologies include Liposome Technology, which acts as a carrier agent, and is designed to enhance the act ion of the active ingredients in its products, and Nanosome Technology, which acts as a delivery vehicle, and is designed to infuse active compounds into targeted cells. The Company products are primarily sold under its DS Laboratories brand. It also sells certain products under its Polaris Labs and Sigma Skin brands. It markets and sells these products through salons, spas, department stores, specialty retailers and distributors. The Company offers products under three product categories: Hair Care, Skin Care and Personal Care.
Receive News & Stock Ratings for DS Healthcare Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DS Healthcare Group Inc. and related stocks with our FREE daily email newsletter.